Vyne Therapeutics INC

Yarrow Bioscience, Inc. (now Yarrow Bioscience Operating Company Corp.) announced the completion of its merger with VYNE Therapeutics, securing approximately $200 million in financing and providing an estimated cash runway into 2028, while advancing its lead drug candidate YB-101 for autoimmune thyroid diseases.

Yarrow Bioscience, Inc. announced an exchange of common stock for pre-funded warrants, impacting outstanding share counts and ownership limitations.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics Inc.) announced the closing of its merger with Yarrow Bioscience, Inc. and the commencement of dosing in a Phase 2a/2b trial for YB-101, a potential treatment for Graves' disease and thyroid eye disease.

VYNE Therapeutics is implementing a 1-for-50 reverse stock split and a special cash dividend in preparation for its merger with Yarrow Bioscience, Inc.

VYNE Therapeutics and Yarrow Bioscience have released an investor presentation detailing their proposed merger and Yarrow's lead drug candidate, YB-101, for Graves' Disease and Thyroid Eye Disease.

VYNE Therapeutics announced a special cash dividend of an estimated $16.5 million, or $0.38 per share, in connection with its proposed merger with Yarrow Bioscience.

Yarrow Bioscience, Inc. (formerly VYNE Therapeutics) reported its Q2 2026 results, highlighting the completion of its merger with Yarrow and a continued focus on its lead candidate YB-101, while managing significant accumulated deficits and future funding needs.

VYNE Therapeutics reported a reduced net loss for Q3 2025, but terminated its Phase 2b repibresib trial for vitiligo and faces a partial clinical hold on VYN202, prompting a strategic review and cost reductions.

VYNE Therapeutics reported mixed clinical trial results for VYN202 and repibresib, leading to trial terminations, while implementing cost reductions to extend its cash runway into the first half of 2027.

VYNE Therapeutics announces its Q1 2025 financial results, including a net loss of $8.6 million, and reports a clinical hold on its Phase 1b trial of VYN202 due to testicular toxicity observed in preclinical studies.

VYNE Therapeutics reported a net loss of $12.16 million for the third quarter of 2024, with increased research and development expenses due to ongoing clinical trials.

VYNE Therapeutics reported a net loss of $15.7 million for the first half of 2024, while advancing its clinical programs for VYN201 and VYN202.

VYNE Therapeutics announced a definitive merger agreement with Yarrow Biosciences, shifting its strategic focus to Yarrow's clinical-stage TSHR antibody for Graves Disease, following setbacks in its BET inhibitor programs.

VYNE Therapeutics' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including repibresib gel and VYN202.

VYNE Therapeutics Inc. reports its 2023 financial results and provides updates on its clinical-stage immuno-inflammatory drug development programs, including VYN201 and VYN202.

RTW Fund Group GP, LLC and 1 other reported changes in beneficial ownership of VYNE Therapeutics Inc. common stock on July 29, 2026.

Mona Ashiya, a Director of VYNE Therapeutics Inc., received 15,435 shares of common stock on July 27, 2026.

Tyler Zeronda, a Director of VYNE Therapeutics Inc., received 185,798 shares of common stock on July 27, 2026.

Tyler Zeronda, CHIEF FINANCIAL OFFICER of VYNE Therapeutics Inc., reported a transaction in 22,516 shares of common stock on July 23, 2026.

Iain Stuart, CHIEF SCIENTIFIC OFFICER of VYNE Therapeutics Inc., reported a transaction in 15,405 shares of common stock on July 23, 2026.

Mutya Harsch, CHIEF LEGAL OFFICER AND GC of VYNE Therapeutics Inc., reported a transaction in 22,516 shares of common stock on July 23, 2026.

VYNE Therapeutics Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, and executive compensation, while revealing increasing net losses and a recent Phase 2b trial failure.

VYNE Therapeutics is holding its annual meeting on December 12, 2024, to vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the equity incentive plan.

OrbiMed Advisors LLC and affiliated entities have filed a Schedule 13D, disclosing beneficial ownership of approximately 9.97% of Yarrow Bioscience, Inc. common stock following a merger.

AI Biotechnology LLC and affiliated entities report a 6.02% stake in Yarrow Bioscience, Inc. following a merger and stock split.

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Yarrow Bioscience, Inc. common stock as of June 30, 2026.

Zhang Xiaofan has filed a Schedule 13G, reporting beneficial ownership of 0.6% of Yarrow Bioscience, Inc. common stock.

Logos Global Management LP and affiliated entities have reported an amendment to their Schedule 13G filing, detailing changes in their beneficial ownership of Yarrow Bioscience, Inc. common stock.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9.99% of Yarrow Bioscience, Inc.'s common stock, holding 266,712 shares and pre-funded warrants.

Logos Global Management LP and affiliated entities have reported beneficial ownership of 9.9% of Yarrow Bioscience, Inc. common stock, including shares and pre-funded warrants.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of Yarrow Bioscience, Inc.'s common stock.